Portrazza
PHONETIC PRONUNCIATION: Portrazza
Description
Portrazza (Necitumumab) is a medication that belongs to a class of drugs known as monoclonal antibodies. It is often used in combination with other drugs to treat non-small cell lung cancer. Uses: Portrazza is used in combination with cisplatin and gemcitabine to treat patients with non-small cell lung cancer (NSCLC). It targets a protein called epidermal growth factor receptor (EGFR), which is overexpressed in many NSCLC tumors. Dosage: The recommended dosage of Portrazza is 800 mg administered as an intravenous infusion over 60 minutes on days 1 and 8 of each 3-week cycle of chemotherapy. The drug is administered in a hospital or medical setting under the supervision of a healthcare provider. Demographic: Portrazza is indicated for use in patients with squamous non-small cell lung cancer who have not received prior chemotherapy for advanced disease. It is not recommended for use in patients with non-squamous NSCLC. Side Effects: Portrazza can cause a range of side effects, some of which may be serious. These can include: - Hypersensitivity reactions - Infusion-related reactions - Cardiopulmonary arrest - Venous thromboembolic events - Hypomagnesemia - Electrolyte abnormalities - Rash - Acneiform rash - Pruritus - Decreased appetite - Fatigue - Nausea - Constipation - Diarrhea - Dyspnea - Epistaxis - Pyrexia Interactions: Portrazza may interact with other drugs, which can affect how the medication works and increase the risk of side effects. Patients should inform their healthcare provider of all medications they are taking, including prescription, over-the-counter, and herbal products. Generic Options: There is currently no generic version of Portrazza available. It is a brand-name medication, meaning it is sold under a specific brand name by a single manufacturer. Patients may be able to find lower-cost alternatives to Portrazza that are equally effective, however, it is important to discuss these options with a healthcare provider before making any changes to a treatment plan. Conclusion: Portrazza is a monoclonal antibody medication used in combination with other drugs to treat squamous non-small cell lung cancer. It is administered via intravenous infusion and can cause a range of side effects, some of which may be serious. Patients should inform their healthcare provider of all medications they are taking and discuss any concerns or questions regarding their treatment plan.
Faq for Portrazza
Portrazza (necitumumab) is a medication used in combination with chemotherapy (cisplatin and gemcitabine) for the treatment of metastatic squamous non-small cell lung cancer (NSCLC) that has not been previously treated.
Portrazza is a monoclonal antibody that targets and blocks the epidermal growth factor receptor (EGFR), a protein involved in cell growth and division. By inhibiting EGFR, Portrazza helps to slow down the growth and spread of cancer cells.
The common side effects of Portrazza include skin rash/acne-like rash, low magnesium levels, diarrhea, vomiting, and low calcium levels. Other side effects may also occur, be sure to consult your healthcare provider about any unusual symptoms.
Portrazza is administered as an intravenous infusion by a healthcare professional. The recommended dose is usually based on your body weight and calculated by your doctor.
Portrazza should be used in combination with chemotherapy (cisplatin and gemcitabine) for the treatment of metastatic squamous NSCLC. It is not recommended for use as a monotherapy.
Before starting Portrazza, it is important to have a thorough medical evaluation, including a heart and lung function assessment. Regular blood tests may be needed to monitor electrolyte levels, especially magnesium and calcium. Regular skin examinations are also recommended.
The duration of Portrazza treatment can vary depending on the individual's response and tolerability. It is typically continued until disease progression or unacceptable toxicity occurs.
Portrazza is contraindicated in patients with severe hypersensitivity reactions to necitumumab or any of its components. It should also not be used in patients with a history of severe infusion reactions or certain pre-existing lung conditions.
Portrazza is not a curative treatment for lung cancer. It is used with chemotherapy to help slow down the progression of metastatic squamous NSCLC and prolong overall survival.